

Ascelia Pharma - SPARKLE is blurred

The required revaluation of a certain number of patients showed a high level of variability and this intra-reader inconsistency will require a re-evaluation of all images by a new group of independent radiology readers. Ascelia plan to give a new update regarding the timelines and the financial implications by mid-September. Our updated view is a base case valuation of SEK 11 (32) and a Bull Case of SEK 28 (100), and a Bear Case of SEK 3 (9).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Ascelia Pharma - SPARKLE is blurred